SAN DIEGO, Sept. 24, 2015 /PRNewswire/ -- ViaCyte, Inc., a privately-held regenerative medicine company with the first pluripotent stem cell-derived islet replacement therapy for the treatment of diabetes in clinical-stage development, today announced three presentations at upcoming healthcare events.
Details of the presentations are as follows:
| Event: |
Accelerating Pathways to Clinical Trials: An International Conference on Islet Regeneration and Replacement |
| Speaker: |
Dr. Kevin D'Amour, Vice President, Research, and Chief Scientific Officer |
| Date/Time: |
September 26, 2015; 9:00 a.m. |
| Location: |
Mayo Clinic Center for Regenerative Medicine, Rochester, Minnesota |
| Event: |
Stem Cell Meeting on the Mesa |
| Speaker: |
Dr. Paul Laikind, President and CEO |
| Date/Time: |
October 7, 2015; 11:45 a.m. |
| Location: |
Estancia La Jolla Hotel and Spa, La Jolla, California |
| Event: |
Cold Spring Harbor Asia/International Society for Stem Cell Research Joint Meeting -- Stem Cells: From Basic Biology to Disease Therapies International Symposium |
| Speaker: |
Dr. Olivia G. Kelly, Senior Director, Cell Biology |
| Date: |
October 22, 2015; 2:00 p.m. |
| Location: |
World Hotel Grand Dushu Lake Suzhou, Suzhou, China |
ViaCyte's VC-01™ product candidate, a first-in-class cell replacement therapy for the treatment of type 1 diabetes, is currently being evaluated in a Phase 1/2 trial called STEP ONE, or Safety, Tolerability, and Efficacy of VC-01 Combination Product in Type One Diabetes.
For more information about ViaCyte's participation in industry events, please visit: http://viacyte.com/news-events-2/viactye-events/
About ViaCyte:
ViaCyte is a privately-held regenerative medicine company focused on developing a novel cell replacement therapy for the treatment of diabetes. ViaCyte is conducting a Phase 1/2 clinical trial of the Company's lead VC-01 product candidate in patients with type 1 diabetes who have minimal to no insulin-producing beta cell function. ViaCyte's VC-01 combination product candidate is based on the production of pancreatic progenitor cells derived from human pluripotent stem cells. These progenitor cells are implanted in a durable and retrievable encapsulation device. Once implanted and matured, these cells are designed to secrete insulin and other regulatory factors in response to blood glucose levels. The VC-01 product candidate is being developed as a potential long-term diabetes treatment with the goals of no immune suppression required, and a reduced risk of hypoglycemia and diabetes-related complications.
ViaCyte is headquartered in San Diego, California with additional operations in Athens, Georgia. The Company is funded in part by the California Institute for Regenerative Medicine (CIRM) and JDRF.
For more information please visit www.viacyte.com. Connect with ViaCyte here: www.twitter.com/viacyte and www.facebook.com/viacyte.
Logo - http://photos.prnewswire.com/prnh/20121026/LA00871LOGO-a
SOURCE ViaCyte
Related Links
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article